For example, the combination of a tumor-targeted antibody with IL2-Fc (bearing D265A mutation to abolish Fc effector function) treatment had superior tumor control, mediated by CD8+T cells, NK cells, macrophages, and polymorphonuclear cells [42]. The gene discussed is CD8A; the disease is neoplasm.